Parents
Sign in to add mentor| Guido Kroemer | grad student | 1997 | University Paris 11 | |
| (Implications des mitochondries au cours du processus apoptotique induit par chimiotherapie antitumorale) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Decaudin D, Dit Leitz EF, Nemati F, et al. (2023) Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103]. European Journal of Cancer (Oxford, England : 1990) |
| Dewaele S, Delhaye L, De Paepe B, et al. (2021) The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival. Oncogene |
| Coussy F, El-Botty R, Château-Joubert S, et al. (2020) BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. Science Translational Medicine. 12 |
| Decaudin D, Frisch Dit Leitz E, Nemati F, et al. (2020) Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. European Journal of Cancer (Oxford, England : 1990). 126: 93-103 |
| De La Rochere P, Guil-Luna S, Decaudin D, et al. (2018) Humanized Mice for the Study of Immuno-Oncology. Trends in Immunology |
| Maubant S, Tahtouh T, Brisson A, et al. (2018) LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. Oncotarget. 9: 22586-22604 |
| Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, et al. (2016) The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget. 7: 23633-46 |
| Carita G, Leitz EFD, Dahmani A, et al. (2016) Abstract 3027: Dual inhibition of PKC and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma Cancer Research. 76: 3027-3027 |
| Diallo B, Massonnet G, El-Botty R, et al. (2016) Abstract 2087: The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma Cancer Research. 76: 2087-2087 |
| Arrouss I, Decaudin D, Choquet S, et al. (2015) Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia. Protein and Peptide Letters. 22: 539-46 |